We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
- Authors
Kris, Mark G; Natale, Ronald B; Herbst, Roy S; Lynch, Thomas J, Jr; Prager, Diane; Belani, Chandra P; Schiller, Joan H; Kelly, Karen; Spiridonidis, Harris; Sandler, Alan; Albain, Kathy S; Cella, David; Wolf, Michael K; Averbuch, Steven D; Ochs, Judith J; Kay, Andrea C
- Abstract
More persons in the United States die from non-small cell lung cancer (NSCLC) than from breast, colorectal, and prostate cancer combined. In preclinical testing, oral gefitinib inhibited the growth of NSCLC tumors that express the epidermal growth factor receptor (EGFR), a mediator of cell signaling, and phase 1 trials have demonstrated that a fraction of patients with NSCLC progressing after chemotherapy experience both a decrease in lung cancer symptoms and radiographic tumor shrinkages with gefitinib.
- Publication
JAMA, 2003, Vol 290, Issue 16, p2149
- ISSN
1538-3598
- Publication type
Journal Article
- DOI
10.1001/jama.290.16.2149